Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lazertinib - Janssen Biotech/Yuhan

Next Previous
Drug Profile

Lazertinib - Janssen Biotech/Yuhan

Alternative Names: C-18112003-G; GNS 1480; JNJ 73841937; JNJ-1937; JNJ-73841937-AAA; Lazertinib mesylate monohydrate; Leclaza; YH-25448

Latest Information Update: 25 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oscotec
  • Developer Janssen Biotech; Janssen Research & Development; Memorial Sloan-Kettering Cancer Center; Yuhan
  • Class Amides; Aniline compounds; Antineoplastics; Dimethylamines; Ethers; Morpholines; Pyrimidines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer

Most Recent Events

  • 31 Dec 2023 Preregistration for Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in European Union (PO) in Q4 2023
  • 23 Oct 2023 Efficacy and adverse event data from a Phase III clinical trials in Non-small cell lung cancer released by Janssen
  • 20 Oct 2023 Updated efficacy data from the phase III MARIPOSA trial in Non-small cell lung cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top